Lisraya Tablet, Film Coated
Product Images NDC 87211-030

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Lisraya (NDC 87211-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Priovant Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure Of Brepocitinib Tosylate (Tra1k 0002 01)

Chemical structure diagram showing the molecular structure of brepocitinib, the active ingredient in LISRAYA 30 mg oral tablets by Priovant Therapeutics, Inc.*

FDA Label Image

Figure (Tra1k 0002 02)

A line graph comparing Total Improvement Score (TIS) LS Mean with 95% Confidence Interval over a 52-week period for LISRAYA (brepocitinib) 30 mg tablets versus placebo in a clinical study. The graph shows higher improvement scores for LISRAYA compared to placebo at each time point.*

FDA Label Image

Principal Display Panel (30 mg Carton Label)

LISRAYA 30 mg (brepocitinib) tablets packaging label showing NDC 87211-030-30. The label indicates the product is an oral film-coated tablet with 30 tablets per package. It includes storage instructions, a barcode, and manufacturer information for Priovant Therapeutics, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.